All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 2.9% on Wednesday following a stronger than expected earnings ...

A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most number of shares in the company, around 68% to be precise, is institutions.

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Yesterday, the company reported ... and mucosal healing, said Pfizer. The drugmaker said that the results suggest etrasimod could offer a "best-in-class" profile for UC, particularly as the ...

Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 to $29.00 in a research report issued on Tuesday,Benzinga reports. The ...

With the data on the study’s other goals in hand, Pfizer said it plans to discuss with the FDA the potential for full approval of Braftovi in metastatic colorectal cancer. The company also plans ...